Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Nemaura Medical Accelerates Launch of sugarBEAT Wearable Continuous Glucose Monitor

Shares of Nemaura Medical traded 20% higher after the firm reported that it is investigating using its non-invasive continuous glucose monitor sugarBEAT® jointly with its planned health subscription service BEAT®diabetes, to provide personalized lifestyle c...
Streetwise Reports | February 27, 2020 |

GlucoTrack: Company Addresses the Diabetes Testing and Monitoring Conundrum

GlucoTrack ( NDAQ:GCTK ) is an American medical device company focused on design, development and commercialization. The company is developing proprietary painless and non-invasive blood glucose monitoring devices for both Type 2 diabetes and prediabetes, a market almost ...
Simon Druker | January 16, 2023 |

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. Yesterday afternoon, The Woodlands, Tex.-based Lexicon Pharmaceu...
Streetwise Reports | September 12, 2019 |

Oil’s Crisis Spikes and the Impact on the Gold Price

At the time, the book was ground-breaking. Back in 2007, Nassim Taleb published a book called The Black Swan: The Impact of the Highly Improbable . He promoted not to try and speculate or predict wild, outlier type events… but to prepare and plan for them. The 20...
Marin Katusa | September 20, 2019 |

Gold Spikes on the Saudi Oil Attacks: Can It Last?

On the weekend, there was a drone attack against the world’s largest oil processing facility and a major oilfield in Saudi Arabia. Oil prices have predictably spiked, but how will this geopolitical shock affect the gold market in the days ahead? What Happene...
Arkadiusz Sieron | September 17, 2019 |

Dexcom Posts 49% YoY Revenue Growth, Sending Shares to 52-Week High

Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance. Glucose monitoring systems maker Dexcom Inc. (DXCM:NASDAQ) yesterday announced financial results for its third quarter ...
Streetwise Reports | November 8, 2019 |

vTv Therapeutics' Shares open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. Clinical-stage pharmaceutical company focused on treating ...
Streetwise Reports | February 11, 2020 |

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. Insulin delivery and diabetes medical device mak...
Streetwise Reports | August 6, 2019 |

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. In an April 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed the reasons why Galmed Pharmaceuticals Ltd. (GLMD:NASDAQ) is "high on the...
Streetwise Reports | April 18, 2019 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |
1 2 3 4 5 6 7